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doi:10.101Busulfan Dosing in Children with BMIs $85%
Undergoing HSCT: A New Optimal Strategy
Brittan Browning,1 Kimberly Thormann,2 Amy Donaldson,1 Terri Halverson,3
Marie Shinkle,2 Morris Kletzel2,3Childhood obesity has more than tripled in the past 30 years. The prevalence of overweight and obese chil-
dren has also increased in the pediatric cancer setting, causing substantial concern over proper chemother-
apeutic dosing in this population. The purpose of this study was to determine if children with an increased
body mass index (BMI) have an alteration in busulfan pharmacokinetics during hematopoietic stem cell trans-
plant (HSCT) conditioning. We retrospectively reviewed data on busulfan pharmacokinetics (PK) on HSCT
subjects (subjects were part of a prospective study previously reported by our group at Children’s Memorial
Hospital) to determine appropriateness of dosing. Subjects were divided into appropriate BMI categories
(\25th percentile, 25th-85th percentile, $85th percentile) and busulfan PK dosing was analyzed (test
dose, regimen dose, area under the curve [AUC], and clearance). The dosing based on PK test dose data
of children with BMI $85% was compared against the package insert dosing recommendations of using ad-
justed ideal body weight (AIBW) in obese patients to determine which dosing schema was most accurate.
Children with high BMIs had higher AUCs when dosing on actual weight then their normal or low BMI coun-
terparts. This indicates that children with a high BMI require less drug (2.9 mg/kg using actual body weight) to
achieve the same AUC as children with normal BMI (4.0 mg/kg) or low BMI (3.6 mg/kg). Using the recom-
mended AIBWdosing schema, 53% of the patients with high BMIs would have had regimen dose AUCs$20%
over/under the target; whereas with the PK test dose method, only 16% of the patients with high BMIs had
regimen dose AUCs$20% over/under the target. PK testing continues to be the gold standard for busulfan
dosing in children. Particular vigilance should be paid to PK monitoring in high BMI categories because of the
potential risk of imprecise dosing when using the AIBW schema.
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The rate of obesity in children is a continually
growing problem in the United States and Western
world. The rate of childhood obesity has more than
tripled in the past 30 years. The prevalence of pediatric
obesity, age 6 to 11 years, has increased from 6.5% in
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6/j.bbmt.2011.01.013among adolescents age 12 to 19 years increased from
5% to 18.1% during that same time period [1,2]. A
total of 9.5% of infants and toddlers are .95th
percentile on weight-for-length growth charts, indi-
cating nearly 10% of this population is obese. A total
of 31.7 % of children aged 2 to 19 years are greater
than the 85th percentile on standard body mass index
(BMI) growth charts, which indicates over 30% of
the pediatric population is overweight or obese [3].
The effect of obesity on pharmacokinetics of drug
absorption, distribution, metabolism, and elimination
(ADME) has been studied in adults. It has been
observed that drug absorption is rarely affected by
obesity. Alternatively, drug distribution is variable
depending on tissue size and permeability, plasma
protein binding, and drug affinity for the tissue com-
partment, all of which are affected to some degree by
obesity. Obesity can cause development of fatty liver
infiltrates, alterations in liver and cardiac blood flow,
and shifts in overall substrate metabolism, which in
turn, affects the metabolism of drugs. In addition, obe-
sity may cause an increase in renal tubular secretion1383
1384 Biol Blood Marrow Transplant 17:1383-1388, 2011B. Browning et al.and a decrease in tubular reabsorption, both of which
alter the elimination of drug compounds [4].
Therapeutic drug monitoring (TDM) has been
used for multiple compounds in the adult and pediat-
ric cancer setting. TDM has been shown to improve
overall survival (OS), event-free survival (EFS), and
in the case of busulfan (BU), sinusoidal obstruction
syndrome–free survival [5-7].
Gibbs et al. [8] observed oral BU clearance (mL/
min) was increased 16.2% in adult obese patients ver-
sus their normal-weighted counterparts. However,
most studies on TDM have been done in adult popu-
lations. There is very little information on drug clear-
ance in overweight/obese pediatric patients, and what
does exist is compound specific, and the results are dif-
ficult to generalize.
The purpose of this investigation was to determine
if children with high BMIs have an alteration in Bu
pharmacokinetics (measured by altered area under
the curve [AUC]) compared to children who have nor-
mal or low BMIs.
METHODS
Todetermine the appropriate dosing for BU in chil-
dren with high BMIs, a retrospective chart review of 68
pediatric patients from Children’s Memorial Hospital
(CMH) was undertaken. These children were a subset
of a prospective study of reduced-intensity conditioning
(RIC) for hematopoietic stem cell transplant (HSCT)
carried out between July 2003 andMay 2008, which in-
cluded a test dose of Bu in children with malignant and
nonmalignant disorders [9]. Signed informed consent
(and adolescent assent when applicable) was obtained
for record reviewat the timeof transplantation in compli-
ance with the hospital’s institutional review board policy.
In the RIC study, the actual body weight (ABW)
was used to determine the BU test does (TD), and
then the BU regimen dose (RD) was adjusted depend-
ing on the pharmacokinetic (PK) results from the TD.
The TD was administered prior to the RD, allowing
for PK analysis to determine the targeted single daily
dose of BU. The following is the procedure used for
the administration of the TD and the RD of BU.
Test Dose
Subjects received a TD of BU infused intravenously
(i.v.) over 3 hours at 0.8 mg/kg, 5 to 7 days before begin-
ning their regimen dose. The expected AUC for the TD
was 1000 mmol/min. Whole-blood samples were drawn
from a separate i.v. catheter than the catheter used for in-
fusing BU at the following time points: 3, 3.5, 5, and 7
hours fromthe startof the infusion.Plasmawas separated
by centrifugation at 2500 rpm for10minutes at 4C.The
processed plasma was split into cryovials and stored at
220C. Samples were shipped to Seattle Cancer Care
Alliance Clinical Pharmacokinetics Laboratory, Seattle,Washington, for analysis.TheAUCand clearance infor-
mation from the TD were provided to the SCT team.
The AUC of the TD was used to calculate the RD of
BU for the conditioning therapy by the clinical care
team atCMH.The predicted target AUC from the stan-
dard TD of 0.8 mg/kg was 800 to 1200 mMol/min.
Calculation of the AUC, Clearance, and Dose
Modification Criteria
Clearance and bioavailability was calculated from
the first dose by fitting a biexponential equation with
the RSTRIP program (MicroMath, Salt Lake City,
UT) to the data. AUC was calculated by trapezoidal
approximation and extrapolation based on computer-
generated parameters from 0 to infinity. The clearance
was calculated using the dose given divided by the
weight and then divided by the AUC. On the basis of
these parameters of the test dose, the dose was modi-
fied to achieve an optimal AUC for the single daily
dose administration [10].
Regimen Dose
The RDwas given on day25,24 of the SCT con-
ditioning regimen that included either fludarabine
(Flu) 30mg/m2 from day210 to day25 and rabbit an-
tithymocyte globulin 2 mg/kg on days24 to21 or ex-
tracorporeal photopheresis (ECP) on day 215 to day
214 and Flu 30 mg/m from day 26 to day 22. The
BU was infused i.v. over 3 hours. The target AUC
for the RD was 4000 mm/min (n 5 51) or 5000 mm/
min (n 5 17) 6 800 mm/min. Whole-blood samples
were drawn at the following time points for pharmaco-
kinetic testing: 3, 3.5, 5, 8, and 24 hours from the start
of the infusion on the first day of the regimen dose.
Samples were processed in the same manner as the
TD and sent to Seattle Cancer Care Alliance Clinical
Pharmacokinetics Laboratory, Seattle, Washington,
for analysis. Because of the time for transport and anal-
ysis bySeattle, itwas not possible to use the information
obtained from theRDPKs for further dose adjustment.
Therefore, only 1 day of RD PK sampling was done.
In addition to the AUC, drug clearance, actual doses
given for the BUTD and RD, the following parameters
were collected from the medical record: date of birth,
sex, date of SCT, height, weight, liver function tests
(AST/ALT), and administration of concomitant medi-
cations (phenytoin, acetaminophen, cyclophosphamide,
fluconazole, or voriconazole).
BMI Categories
BMI {wt (kg)/[height (m)]2} for children 2 to 19
years of age or weight-for-length percentile for chil-
dren 0 to 2 years of age was determined from the re-
corded height and weight at the time of test dose.
The children’s BMI or weight for length was graphed
on a standard Centers for Disease Control (CDC)
Table 1. Patient Characteristics, N 5 68
Variable
Measures
n %
Sex
Female 27 39.7
Male 41 60.3
ALT
Elevated 17 25.4
Not elevated 50 74.6
AST
Elevated 13 19.4
Not elevated 54 80.6
Received fluconazole or voriconazole
Yes 39 60.0
No 26 40.0
Diagnosis of malignancy
Yes 37 54.4
No 31 45.6
Biol Blood Marrow Transplant 17:1383-1388, 2011 1385Busulfan Dosing in Children with BMIs $85% Undergoing HSCTgrowth chart. The subjects were divided into 3 BMI
categories based on the percentiles established from
the growth chart or BMIs:\25th percentile (under-
weight), 25 to\85th percentile (normal weight), and
$85th percentile (overweight/obese).
Calculated Dose for Adjusted Ideal BodyWeight
(IBW)
It is customary to administer 0.8 mg/kg as a single
daily dose of BU for the RD to target an AUC of 1000
mmol/min if TD PKs are not available. The package
insert recommends using an adjusted ideal body weight
(adjusted ideal body weight [AIBW] 5 IBW 1 0.25 
[actual weight-IBW]) for obese adults. IBWwas deter-
mined in patients\2 years old per growth chart; in pa-
tient $2 years old, Traub and Johnson (1980)
equations were utilized: patients 2 years old to 5 feet
tall (IBW [kg] 5 ht2 [in cm]  1.65/1000); males .5 ft
(IBW [kg] 5 391 [2.27  inches over 5 feet]); and
female (IBW [kg]5 42.21 [2.27 inches over 5 feet]).
We compared these na€ıve dose calculations and
the actual RD given based on TD PK results to the
ideal dose for all children with BMI $85th percentile.
The ideal dose was determined based on an AUC
target of 4000 mm/min or 5000 mm/min per protocol
using the RD PK data.
Statistical Analysis
We summarized subject and treatment characteris-
tics using summary counts and percentages for categor-
ical measures and the mean 6 standard deviation for
continuous measures. We compared the mean dose,
clearance, and AUCby BMI category and evaluated dif-
ferences using analysis of variance. The data were then
analyzed to determine which factors were associated
with either over or under estimating the predicted (tar-
get AUC) for the test dose. We first looked at whether
the actualAUCwas lower than the predictedAUCcom-
pared to targetorhigher thanpredicted.We then looked
atwhether the actualAUCwashigher than thepredicted
AUC compared to target or lower than predicted.
Significance of associations were assessed by the
chi-square test or the Fisher’s exact test, as appropri-
ate. A significance level of .05 was used for all analyses.
The primary variable of interest was BMI category. Al-
though testing was performed for additional variables,
no adjustments were made for multiple comparisons
based on the exploratory nature of these investigations.BMI category (percentile)
<25th 17 25.0
25th to <85th 29 42.6
$85th 22 32.4
Extreme BMI category (percentile)
0 to 5th 6 8.8
>5th to <95th 49 72.1
$95th 13 19.1
BMI indicates body mass index; AST, aspartate aminotransferase; ALT,
alanine aminotransferase.RESULTS
The characteristics of the study population are
outlined in Table 1. The ages ranged from 0 to 21
years; the average age was 7.1 6 6.1 years. Weight
ranged from 2.5 to 117.8 kg, with a mean of 30.6 kg.
Fifty-four percent of patients had amalignant diagnosis.Breakdown of BMI categories was as follows: n 5 17
(25%) \25th percentile, n 5 29 (43%) between the
25th and 85th percentile, and n5 22 (32%)$85th per-
centile. Of the subjects with BMIs\25th percentile,
65% had nonmalignant disorders. In contrast, of the
subjects with BMIs$85th percentile, 82% had amalig-
nant disorder. Children under 4 years of age were 53%
of the\25th percentile, 45% of the 25th to 85th per-
centile, and 18%of the$85th percentile. The source of
stem cells was matched related donor (MRD) in 47%,
matchedunrelateddonor (MUD) in38%, andumbilical
cord blood (UCB) in 15%. Conditioning was Flu/BU/
antithymocyte globulin (ATG) in 71% and Flu/BU/
ECP in 29%. Further information on the timing of
agents used in conditioning is outlined in Table 2.
Table 3 outlines the diagnoses for all subjects in
this investigation and their corresponding BMI cate-
gories.
Table 4 outlines the characteristics of the TD and
RDby BMI category. All children were given a BUTD
based on protocol (0.8 mg/kg). The BU RD and clear-
ance varied significantly by subject size, with the lowest
dose (2.9 mg/kg) and lowest clearance (3.1 ml/min/kg)
in the patients with BMIs $85th percentile.
Table 5 presents the associations between patient
characteristics and AUC under or over target for the
test dose. Note that there was no significant associa-
tion between BMI category and being over or under
target for the TD AUC. We did observe that those
who received fluconazole/voriconazole were less likely
to have a high TD AUC (P 5 .05). There was also an
association between a low TD AUC and the diagnosis
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1386 Biol Blood Marrow Transplant 17:1383-1388, 2011B. Browning et al.of malignancy, namely, 11% of the children with a di-
agnosis of malignancy were under target for TDAUC,
compared to 46%of those who did not have a diagnosis
of malignancy (P 5 .002). Also, those with elevated
AST were less likely to have a low TD AUC (P 5
.03). Figure 1 shows the relationship between TD
AUC and RD AUC targets.
Nineteen patients with BMIs$85th percentile had
complete PK data from both the TD and RD. These
patients’ RD (based on PKs from the TD) was com-
pared against the calculated dose using the package
insert recommendation of AIBW to determine which
dosing schema was most accurate. The recommended
AIBWdosing schemawould have resulted in a regimen
dose AUC $20% over or under the target AUC in 10
of the 19 patients (53%) with BMs $85th percentile,
whereas the PK test dose method resulted in RD
AUCs $20% over or under the target AUC in 3 of
the 19 patients (16%) with BMIs $85th percentile.
The mean dose (mg/kg) based on actual body weight
using the AIBW scheme would have been 2.7 mg/kg/
actual body weight, which is less than the 3.1 mg/kg/
actual body weight given for the RD based on TD
PK data. The mean percentage over or under the tar-
get AUC for the regimen dose would have been 23.3%
using the AIBW dosing scheme compared to 10.7%
when TD PK data was used. When the children
were broken into a more extreme weight category
$95th percentile, the results were consistent.
Age is a known variable in BU dosing. The data
were also analyzed for children\4 and children .4.
children under 4 were more likely to have an AUC be-
low target for the TD. All children received the same
test dose of BU 0.8 mg/kg regardless of age.DISCUSSION
In this investigation, children with a high BMI had
higher AUCs when dosing on actual body weight than
their normal or low BMI counterparts, indicating
higher drug exposure in the larger children.Conversely,
childrenwith a highBMI required less drug (2.9mg/kg)
to achieve the same AUC as normal BMI children (4.0
mg/kg) or low BMI children (3.6 mg/kg). When the
children were broken into more extreme weightTable 3. Diagnosis
Diagnosis (N) %
Leukemia (ALL, AML, CML) 23 33.8
Genetic disorders 17 25.0
SCID 11 16.2
Preleukemia (MDS, FHLH, AA) 8 11.8
Lymphoma 5 7.4
Solid tumors 4 5.9
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myeloid leukemia; SCID, severe combined im-
munodeficiency; MDS, myelodysplastic syndrome; FHLH, familial hemo-
phagocytic lymphohistiocytosis; AA, aplastic anemia.
Table 4. Patient Distribution by BMI and the Measurment of
the AUC of the Test Dose and the Regimen Dose by Patient
Size and by BMI Category
BMI Category (Percentile)
<25 (n 5 18) 25 to < 85 (n 5 29) $85 (n 5 22)
mean ± SD mean ± SD mean ± SD P
Test dose
Clearance 3.7 ± 0.6 3.8 ± 1.0 3.2 ± 1.0 .10
AUC 917 ± 187 879 ± 211 1086 ± 362 .03
Regimen dose
mg/kg 3.6 ± 0.7 4.0 ± 1.1 2.9 ± 1.1 .001
Clearance 4.0 ± 1.1 3.8 ± 1.1 3.1 ± 1.1 .03
AUC 3709 ± 798 4397 ± 965 4110 ± 675 .07
AUC indicates area under the curve.
Biol Blood Marrow Transplant 17:1383-1388, 2011 1387Busulfan Dosing in Children with BMIs $85% Undergoing HSCTcategories (\5th percentile, 5 to\95th percentile, and
$95th percentile), the results were consistent except
that children with low BMI required the highest dose.
It was also determined from this investigation that
the method of dosing children in the$85th percentile
according to the package insert equation (AIBW 5
IBW 1 0.25  [actual weight-IBW]) proved an in-
accurate way of determining dosing for i.v. BU. Our
investigations showed the AIBWmethod can both un-
der-dose and overdose these children compared to an
RD determined by modification to a PK TD. Based
on the results of this investigation, AIBW dosing
should only be used in circumstances where a TD is
not available (because of PK sampling error) and
should not be routinely used without determining
the optimal RD from PK TD data.Table 5. Association between Patient Characteristics and
AUC Under or Over Target for the Test Dose
Test Dose
Under Target Over Target
Patient Characteristics n (%) P n (%) P
Age
<4 years 10 (42%) 2 (8%)
$4 years 7 (18%) .04 7 (18%) .46
Sex
Female 5 (19%) 3 (12%)
Male 12 (32%) .25 6 (16%) .60
ALT
Elevated 5 (31%) 2 (13%)
Not elevated 12 (26%) .75 7 (15%) 1.00
AST
Elevated 0 (0%) 3 (27%)
Not elevated 17 (33%) .03 6 (12%) .19
Received fluconazole/voriconazole
Yes 11 (31%) 2 (6%)*
No 6 (25%) .64 6 (25%)* .05
Diagnosis of malignancy
Yes 4 (11%) 7 (20%)
No 13 (46%) .002 2 (7%) .28
BMI category (percentile)
<25th 3 (20%) 1 (7%)
25th to <85th 10 (36%) 2 (7%)
$85th 4 (20%) .38 6 (30%) .09
BMI indicates body mass index; AST, aspartate aminotrasnferase; AlT,
alanine aminotransferase.
*One subject is missing ALT/AST data.The diagnosis of malignancy and under TD target
was also found to be statistically significant. It has
been shown that obesity causes alterations in themetab-
olism and excretion of pharmacologic agents. We also
know from this investigation that older children were
also more likely to have malignant disorders. We can
speculate that these children have received more che-
motherapeutic agents, which combined with increased
BMImay cause changes toBUmetabolismor excretion.
When considering the relationship between other
characteristics and the TD AUC, we found no statisti-
cal association for age, sex, source of stem cells, RIC
regimen, or concomitant medications (cyclophospha-
mide, phenytoin, and acetaminophen). There was, an
association between the administration of fluconazole
or voriconazole and a high TD AUC. Itraconazole,
and to a lesser extent, fluconazole, are known to be po-
tent inhibitors of the CYP3A4 system where BU is
likely metabolized; therefore, these results were not
surprising [11]. Buggia et al. [12] determined that the
concurrent administration of itraconazole decreased
BU clearance by approximately 20%. Although this ef-
fect was not as clearly seen with fluconazole in that
study, chemical similarities between the compounds
could explain this result.
The relationship between elevated AST and low
TD AUC is unknown because none of these patients
had obvious liver dysfunction. The patients all had
pre-evaluation studies with no clinically significant re-
ported abnormalities in the bilirubin, ALT/AST, and
clotting studies (.2  upper limit of normal).
Of the children who had a low BMI, the majority
(65%) had nonmalignant diseases. This would be ex-
pected because most of these children suffered from
severe combined immune deficiency (SCID) or other
metabolic disorders that often cause failure to thrive.
In contrast, for children with a high BMI, 82% had
a malignant disorder. This observation was surprising,
as many of these children had received prior chemo-
therapy, which often results in nausea, vomiting, an-
orexia, cachexia, and subsequent weight loss. ThereFigure 1. Busulfan dosing trends.
1388 Biol Blood Marrow Transplant 17:1383-1388, 2011B. Browning et al.are 3 possible explanations for this observation. First,
these children may have experienced chemotherapy-
induced side effects but were actually even more over-
weight when they began their disease treatment with
subsequent weight loss before SCT but who still re-
mained above the 85th percentile for BMI. Another
possibility is that newer chemotherapeutic agents, bet-
ter antinausea medications, and novel dosing schemes
are reducing these traditional chemotherapy-induced
side effects, that is, children are losing less weight
with chemotherapy. Finally, steroid-induced weight
gain for children diagnosed with leukemia could also
explain the reason why some children did not lose
weight and may have gained weight during their che-
motherapy regimen.
Another interesting observation is the rate of over-
weight/obesity (BMI$85th percentile) for this cohort
was 32%, which closely mimics the national rate of pe-
diatric obesity of about 30% [1]. This indicates the
dosing of chemotherapy agents in overweight and
obese patients is likely to be a continuing concern as
the rates of pediatric obesity continue to rise in the
general population.
Several interesting dosing trends were also ob-
served. Whether patients were below the target or on
target for the TD AUC, by using the TD PK data the
clinicianswere able to correct theRDAUCtobeon tar-
get.80%of the time. In addition, if the childwas above
the target AUC on the TD, they were on target for the
RD AUC. This could indicate that the clinicians were
more accurate in correcting for a high TD AUC than
a low or on target TD AUC. However, a larger study
wouldbeneeded to see if thiswas statistically significant.
Vassal et al. [13] recently published an article of al-
ternative dosing strategies using body weight instead
of TDM to reduce variability of dosing. This investi-
gation was based on BU administration every 6 hours
over 4 days using 5 dosing levels. This investigation
concluded that TDM was not necessary to achieve
optimal dosing. Although this methodology may be
effective in the every 6-hour dosing of BU, we cannot
extrapolate this information to once every 24-hour
dosing, which was used in this study.
We concede that there are some significant limita-
tions to this study. First, the sample size was limited.
Althoughwebelieve this is the largest single-institution
pediatric cohort for once-daily BUdosing, it is possible
the small sample size has affected the outcome. A larger
sample size would also have allowed us to look at more
gradation in weight categories, further separating out
the lower and upper weight categories and would pro-
vide increased power to examine predictors of over- or
underdosing. An additional limitation is the number
of statistical tests performed. Because this was an ex-
ploratory and descriptive analysis, we did not adjust
for multiple testing, and it is possible that some of the
results observed are simply because of chance.CONCLUSIONS
In conclusion, children with a high BMI require less
i.v. BU than children with normal or low BMI to achieve
the same AUC and therapeutic drug levels even after TD
adjustments. The traditional dosing schema of 3.2 mg/kg
in the RD could possibly overdose children with high
BMIs.We recommend the continued use of a TD to de-
termine thecorrectRDinall childrenreceivingonce-daily
i.v. BU. We discourage the routine use of 3.2 mg/kg
AIBWfor theRDasour investigationhas shownpotential
for overdosing children with high BMIs. The results of
this investigation also show the importance of continued,
vigilant pharmacokinetic monitoring in this population.ACKNOWLEDGMENT
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